On the 23rd of March, Point72 Asset Management bought 1.3 million Tricida , Inc. (NASDAQ:TCDA) shares for $6.6 million at an average price of $5.01 per share. Shares of Tricida,...
On the 22nd of March, Point72 Asset Management purchased 5.3 million Curis Inc (CRIS) shares for $68 million at an average price of $12.77 per share. Shares of Curis Inc are down...
CytomX Therapeutics (NASDAQ:CTMX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one...
CytomX Therapeutics, Inc. (NASDAQ:CTMX) and Japan-based Astellas Pharma entered into a strategic collaboration for discovering, developing and commercialization of novel T-cell...
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.